Cardiovascular events after polychemotherapy of multiple myeloma: modern ways to diagnostics

Authors

  • B. B. Samura Zaporizhzhia State Medical University, Ukraine,
  • M. O. Panasenko Zaporizhzhia State Medical University, Ukraine,

DOI:

https://doi.org/10.14739/2409-2932.2020.1.198217

Keywords:

multiple myeloma, cardiovascular events, chemotherapy, diagnostics, prognostic factors

Abstract

Heart dysfunction that occurred after using cytostatic drugs and monoclonal antibodies may be a limit factor in the treatment of multiple myeloma. Side effects of chemotherapy include hypotension, hypertension, arrhythmias, conduction disturbances, pericarditis, thromboembolic events, heart failure, death.

The risk of cardiotoxicity may be increased by some factors that include drug exposure, age, history of heart diseases, arterial hypertension, drug combination, previous radiotherapy or chemotherapy. It’s important to detect cardiovascular toxicity before the appearance of clinical signs of heart and vessel disturbance. The role of markers in the elicitation of risk groups of cardiovascular events is uncertain yet.

Early diagnostics and definition of prognostic factors of cardiovascular toxicity appeared after polychemotherapy of oncohematological diseases are important and not solve problems.

 multiple myeloma, cardiovascular events, chemotherapy, diagnostics, prognostic factors.

References

  1. Bazyka, D. A., Gudzenko, N. A., Dyagil, I. S., Babkina, N. G., Chumak, V. V., Bakhanova, E. V., Paramonov, V. V., & Romanenko A. Ye. (2013). Multiple myeloma among chornobyl accident clean, up workers – state and perspectives of analytical study. Problemy radiatsiinoi medytsyny ta radiobiolohii, (18), 169-172. [in Ukrainian].
  2. Pazina, T. Yu., Korneva, E. A., Orlov, D. S., & Shamova, O. V. (2017). Mnozhestennaja mieloma: patogenez i novye podhody k terapii [Multiple myeloma: pathogenesis and new approaches to therapy]. Patogenez, 15(1), 4-10. [in Russian].
  3. Osborne, T. R., Ramsenthaler, C., de Wolf-Linder, S., Schey, S. A., Siegert, R. J., Edmonds, P. M., & Higginson, I. J. (2014). Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. Bmc Cancer, 14, Article 496. https://doi.org/10.1186/1471-2407-14-496
  4. Ewer, M. S., & Ewer, S. M. (2015). Cardiotoxicity of anticancer treatments. Nature Reviews Cardiology, 12(9), 547-558. https://doi.org/10.1038/nrcardio.2015.65
  5. Heckmann, M. B., Doroudgar, S., Katus, H. A., & Lehmann, L. H. (2018). Cardiovascular adverse events in multiple myeloma patients. Journal of Thoracic Disease, 10, S4296-S4305. https://doi.org/10.21037/jtd.2018.09.87
  6. De Stefano, V., Za, T., & Rossi, E. (2014). Venous Thromboembolism in Multiple Myeloma. Seminars in Thrombosis and Hemostasis, 40(3), 338-347. https://doi.org/10.1055/s-0034-1370793
  7. Cornell, R. F., & Kassim, A. A. (2016). Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplantation, 51(4), 479-491. https://doi.org/10.1038/bmt.2015.307
  8. Vatutin, N. T., Sklyanaya, E. V., Shevelek, A. N., Smirnova, A. S., El'-Khatib, M. A., Gritsenko, Yu. P., Kolesnikov, V. S., & Taratorina, A. A. (2017). Preparaty, vyzyvayushchie ili ukhudshayushchie techenie serdechnoi nedostatochnosti. Obzor rekomendatsii Amerikanskoi assotsiatsii serdtsa [Drugs That May Cause or Exacerbate Heart Failure. A Scientific Statement from the American Heart Association. Circulation]. Praktychna anhiolohiia, (1), 52-65. [in Ukrainian].
  9. Kevane, B., Crowley, M. P., Bolster, M., & Gilligan, O. (2014). Myeloma Relapse Involving the Heart and Presenting As Acute Cardiac Failure. Journal of Clinical Oncology, 32(18), E67-E68. https://doi.org/10.1200/jco.2012.47.6713
  10. Fowler, N. H., Cheah, C. Y., Gascoyne, R. D., Gribben, J., Neelapu, S. S., Ghia, P., … Dunleavy, K. (2016). Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica, 101(5), 531-540. https://doi.org/10.3324/haematol.2015.139493
  11. Lakomkin, V. L., Abramov, A. A., Gramovich, V. V., Vyborov, O. N., Lukoshkova, E. V., Ermishkin, V. V., & Kapelko, V. I. (2017). Dinamika formirovaniya sistolicheskoi disfunktsii serdtsa pri doksorubitsinovoi kardiomiopatii [The Time Course of Formation Of Systolic Dysfunction of the Heart in Doxorubicin Cardiomyopathy]. Kardiologiia, 57(1), 59-64. [in Russian]. https://doi.org/10.18565/cardio.2017.1.59-64
  12. Akazawa, H. (2017). Cardiotoxicity of cancer chemotherapy – mechanisms and Therapeutic Approach. Gan to kagaku ryoho. Cancer & chemotherapy, 44(13), 2058-2063.
  13. (2017). Likuvannia onkolohichnykh zakhvoriuvan i sertsevo-sudynna toksychnist: Tochka zoru Yevropeiskoho tovarystva kardiolohiv. Ch. 1 [The perspective of the European Society of Cardiologists. Cancer treatment and cardiovascular toxicity. Рart. 1]. Sertse i sudyny, (2), 11-19. [in Ukrainian].
  14. Suter, T. M., & Ewer, M. S. (2013). Cancer drugs and the heart: importance and management. European Heart Journal, 34(15), 1102-1111. https://doi.org/10.1093/eurheartj/ehs181
  15. Postnikov, S. S., Gratianskaya, A. N., & Kostyleva, M. N. (2015). Lekarstvennye bolezni serdtsa i sosudov [Drug diseases of heart and blood vessels]. Pediatria, 94(2), 169-174. [in Russian].
  16. Anokhin, V. N., Chushkin, M. I., & Kolganov, A. V. (2011). Antratsiklinovaya kardiomiopatiya [Anthracycline cardiomyopathy]. Terapevticheskiy arkhiv, 83(10), 72-76. [in Russian].
  17. Amosova, K. M. (2016). Kardiomiopatii: suchasnyi pohliad na pytannia klasyfikatsii, etiolohii, diahnostyky ta dyferentsialnoi diahnostyky [Cardiomyopathies: modern view on the issues of classification, etiology, diagnosis and differential diagnosis. Part 1]. Sertse i sudyny, 2, 7-18. [in Ukrainian].
  18. Ritchie, D. S., Seymour, J. F., Roberts, A. W., Szer, J., & Grigg, A. P. (2001). Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplantation, 28(1), 101-103. https://doi.org/10.1038/sj.bmt.1703098
  19. Skrypnyk, I. M., Maslova, H. S., & Lymanets, T. V. (2016). Ishemichna khvoroba sertsia yak faktor ryzyku antratsyklinindukovanoi kardiotoksychnosti [Ischemic heart disease as a risk factor for anthracycline-induced cardiotoxicity]. Vrachebnoe delo, 5-6, 47-52. [in Ukrainian].
  20. Gulati, A., Jabbour, A., Ismail, T. F., Guha, K., Khwaja, J., Raza, S., … Prasad, S. K. (2013). Association of Fibrosis With Mortality and Sudden Cardiac Death in Patients With Nonischemic Dilated Cardiomyopathy. Jama-Journal of the American Medical Association, 309(9), 896-908. https://doi.org/10.1001/jama.2013.1363
  21. Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., … Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal-Cardiovascular Imaging, 15(10), 1063-1093. https://doi.org/10.1093/ehjci/jeu192
  22. Castel, M., Despas, F., Modesto, A., Gales, C., Honton, B., Galinier, M., Senard, J. M., & Pathak, A. (2013). Cardiotoxicity of chemotherapies. Presse Med, 42(1), 26-39. https://doi.org/10.1016/j.lpm.2012.04.014
  23. Willis, M. S., & Patterson, C. (2013). Mechanisms of Disease Proteotoxicity and Cardiac Dysfunction - Alzheimer's Disease of the Heart? New England Journal of Medicine, 368(5), 455-464. https://doi.org/10.1056/NEJMra1106180
  24. Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., … Investigators, A. (2005). Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352(24), 2487-2498. https://doi.org/10.1056/NEJMoa043445
  25. Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Spicka, I., Oriol, A., … Investigators, A. (2015). Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine, 372(2), 142-152. https://doi.org/10.1056/NEJMoa1411321
  26. Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., … Grp, T.-M. S. (2016). Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine, 374(17), 1621-1634. https://doi.org/10.1056/NEJMoa1516282
  27. Nesen, A. O. (2014). Khronichni neinfektsiini zakhvoriuvannia: aktsent na komorbidnist i pidvyshchenyi kardiovasuliarnyi ryzyk [Chronic non-communicable diseases: accent on comorbidity and increased cardiovascular risk]. Ukrainskyi terapevtychnyi zhurnal, (2), 26-32. [in Ukrainian].
  28. Cardinale, D., Biasillo, G., Salvatici, M., Sandri, M. T., & Cipolla, C. M. (2017). Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Expert Review of Molecular Diagnostics, 17(3), 245-256. https://doi.org/10.1080/14737159.2017.1283219
  29. Chow, E. J., Chen, Y., Kremer, L. C., Breslow, N. E., Hudson, M. M., Armstrong, G. T., … Yasui, Y. (2015). Individual Prediction of Heart Failure Among Childhood Cancer Survivors. Journal of Clinical Oncology, 33(5), 394-402. https://doi.org/10.1200/jco.2014.56.1373
  30. Lipshultz, S. E., Adams, J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., … Council Nutr Phys Activity, M. (2013). Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions A Scientific Statement From the American Heart Association. Circulation, 128(17), 1927-1995. https://doi.org/10.1161/CIR.0b013e3182a88099
  31. Solodiannikova, O. I., Golovko, T. S., Lavryk, G. V., & Shevchuk, L. A. (2012). Vozmozhnosti ekhokardiografii v otsenke kardiotoksichnosti khimioterapevticheskogo lecheniya bol'nykh onkologicheskogo profilya: sostoyanie problemy v literature, rezul'taty sobstvennykh issledovanii [Echocardiography capability in assessment of chemotherapy’s cardiotoxicity of oncologic patients (literature review, results of own examinations)]. Klinicheskaya onkologiya, (8), 144-150. [in Russian].
  32. Fandeev, O. A., Vasechkin, S. S., Alekhin, M. N., Odintsov, S. V., Kallistov, V. E., & Sidorenko, B. A. (2011). Klinicheskoe znachenie kardiotoksichnosti antratsiklinov: sovremennye podkhody k diagnostike, profilaktike i lecheniyu [Clinical Value of Antracycline Toxicity: Modern Approaches to Diagnosis, Prevention, and Treatment]. Kardiologiia, 51(7), 40-46. [in Russian].
  33. Chernov, V. I., Kravchuk, T. L., Zelchan, R. V., & Goldberg, V. E. (2015). Radionuklidnye metody issledovaniya v otsenke kardiotoksichnosti antratsiklina [Radionuclide Methods in the Assessment of Anthracycline-Induced Cardiotoxicity]. Kardiologiia, 55(7), 57-62. [in Russian].
  34. Bellenger, N. G., Burgess, M. I., Ray, S. G., Lahiri, A., Coats, A. J. S., Cleland, J. G. F., Pennell, D. J., & Christmas Study Steering Comm, I. (2000). Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance - Are they interchangeable? European Heart Journal, 21(16), 1387-1396. https://doi.org/10.1053/euhj.2000.2011
  35. Vogel-Claussen, J., Finn, J. P., Gomes, A. S., Hundley, G. W., Jerosch-Herold, M., Pearson, G., … Bluemke, D. A. (2006). Left ventricular papillary muscle mass: Relationship to left ventricular mass and volumes by magnetic resonance imaging. Journal of Computer Assisted Tomography, 30(3), 426-432. https://doi.org/10.1097/00004728-200605000-00013
  36. Thavendiranathan, P., Walls, M., Giri, S., Verhaert, D., Rajagopalan, S., Moore, S., Simonetti, O. P., & Raman, S. V. (2012). Improved Detection of Myocardial Involvement in Acute Inflammatory Cardiomyopathies Using T2 Mapping. Circulation-Cardiovascular Imaging, 5(1), 102-110. https://doi.org/10.1161/circimaging.111.967836
  37. Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., … Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal-Cardiovascular Imaging, 15(10), 1063-1093. https://doi.org/10.1093/ehjci/jeu192
  38. Thavendiranathan, P., Grant, A. D., Negishi, T., Plana, J. C., Popovic, Z. B., & Marwick, T. H. (2013). Reproducibility of Echocardiographic Techniques for Sequential Assessment of Left Ventricular Ejection Fraction and Volumes Application to Patients Undergoing Cancer Chemotherapy. Journal of the American College of Cardiology, 61(1), 77-84. https://doi.org/10.1016/j.jacc.2012.09.035
  39. Samura, B. B., Kolesnyk, Yu. M., & Syvolap, V. V. (2014). Znachennia tsyrkuliuiuchoho halektynu-3 v prohnozuvanni kardiovaskuliarnykh podii u patsiientiv iz khronichnoiu limfotsytarnoiu leikemiieiu v remisii [Value of circulating galectin-3 for prognosis of cardiovascular events in patients with chronic lymphocytic leukemia in remission]. Zaporozhye medical journal, 2014, (6). 44-47. [in Ukrainain].
  40. Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., … Scherrer-Crosbie, M. (2012). Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab. Circulation-Cardiovascular Imaging, 5(5), 596-603. https://doi.org/10.1161/circimaging.112.973321
  41. Voigt, J. U., Pedrizzetti, G., Lysyansky, P., Marwick, T. H., Houle, H., Baumann, R., … Badano, L. P. (2015). Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. European Heart Journal-Cardiovascular Imaging, 16(1), 1-11. https://doi.org/10.1093/ehjci/jeu184
  42. Vizіr, V. A., Popov, V. V., Kopitsa, N. P., & Voloshyna, I. N. (2011). Biomarkery pri serdechnoi nedostatochnosti - novye orientiry lechebnoi taktiki? [Biomarkers in heart failure – new objectives of therapeutic tactics?]. Sertse i sudyny, (2), 108-113. [in Russian].
  43. Berezin, A. E. (2015). Biologicheskie markery v diagnostike, prognozirovanii i otsenke effektivnosti terapii serdechnoi nedostatochnosti s sokhranennoi i snizhennoi kontraktil'noi funktsiei [Biological markers in the diagnosis, prediction and evaluation of the effectiveness of heart failure therapy with preserved and reduced contractile function]. Sertseva nedostatnist, (2), 16-27. [in Russian].
  44. Cardinale, D., Colombo, A., Lamantia, G., Colombo, N., Civelli, M., De Giacomi, G., … Cipolla, C. M. (2010). Anthracycline-Induced Cardiomyopathy Clinical Relevance and Response to Pharmacologic Therapy. Journal of the American College of Cardiology, 55(3), 213-220. https://doi.org/10.1016/j.jacc.2009.03.095
  45. Specchia, G., Buquicchio, C., Pansini, N., Di Serio, F., Liso, V., Pastore, D., … Liso, A. (2005). Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. Journal of Laboratory and Clinical Medicine, 145(4), 212-220. https://doi.org/10.1016/j.lab.2005.02.003
  46. Dorizzi, R. M., Caputo, M., Ferrari, A., Lippa, L., & Rizzotti, P. (2002). Comparison of serum and heparin-plasma samples in different generations of dimension troponin I assay. Clinical Chemistry, 48(12), 2294-2296.
  47. Soker, M., & Kervancioglu, M. (2005). Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Medical Journal, 26(8), 1197-1202.
  48. Suzuki, T., Hayashi, D., Yamazaki, T., Mizuno, T., Kanda, Y., Komuro, I., … Yazaki, Y. (1998). Elevated B-type natriuretic peptide levels after anthracycline administration. American Heart Journal, 136(2), 362-363. https://doi.org/10.1053/hj.1998.v136.89908
  49. Maries, L., & Manitiu, I. (2013). Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovascular Journal of Africa, 24(7), 286-289. https://doi.org/10.5830/cvja-2013-055
  50. Yaris, N., Ceviz, N., Coskun, T., Akyuz, C., & Buyukpamukcu, M. (2002). Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. Journal of Experimental & Clinical Cancer Research, 21(2), 165-170.
  51. Del Pinto, R., & Ferri, C. (2018). Inflammation-Accelerated Senescence and the Cardiovascular System: Mechanisms and Perspectives. International Journal of Molecular Sciences, 19(12), Article 3701. https://doi.org/10.3390/ijms19123701
  52. US Food and Drug Administration. (2013, July 1). 510(k) Substantial Equivalence Determination Decision Summary; K093758. http://www.accessdata.fda.gov/cdrh_docs/reviews/K093758.pdf
  53. Syvolap, V. D., Lashkul, D. A. (2014). Vzaiemozviazky mizh rivnem markeriv fibrozu ST2, halektynu-3, strukturno-funktsionalnymy parametramy livoho shlunochka ta funktsiieiu nyrok pry khronichnii sertsevii nedostatnosti ishemichnoho henezu [The relationship between the level of markers of fi brosis ST2, galectin-3, structural, functional parameters of the left ventricle and renal function in patients with ischemic chronic heart failure]. Zaporozhye medical journal, 2014, (5), 13-17. [in Ukrainian]. https://doi.org/10.14739/2310-1210.2014.5.28742
  54. Sano, H., Hsu, D. K., Apgar, J. R., Yu, L., Sharma, B. B., Kuwabara, I., Izui, S., & Liu, F. T. (2003). Critical role of galectin-3 in phagocytosis by macrophages. Journal of Clinical Investigation, 112(3), 389-397. https://doi.org/10.1172/jci200317592
  55. Krzeslak, A., & Lippinska, A. (2004). Galectin-3 as a multifunctional protein. Cellular & Molecular Biology Letters, 9(2), 305-328.
  56. Samura, B. (2015). Prognosticheskaja rol galektina-3 u pacientov so mnozhestvennoj mielomoj v remissii [The prognostic role of galectin-3 in patients with multiple myeloma in remission]. Zaporozhye Medical Journal, (4), 11-16. [in Russian]. https://doi.org/10.14739/2310-1210.2015.4.50298
  57. van der Velde, A. R., Gullestad, L., Ueland, T., Aukrust, P., Guo, Y., Adourian, A., … de Boer, R. A. (2013). Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure Data From CORONA and COACH. Circulation-Heart Failure, 6(2), 219-226. https://doi.org/10.1161/circheartfailure.112.000129
  58. Amin, H. Z., Amin, L. Z., & Wijaya, I. P. (2017). Galectin-3: A novel biomarker for the prognosis of heart failure. Clujul Medical, 90(2), 129-132. doi:10.15386/cjmed-751
  59. Bentley, K., Franco, C. A., Philippides, A., Blanco, R., Dierkes, M., … Gerhardt, H. (2014). The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesis. Nature Cell Biology, 16(4), 309-321. https://doi.org/10.1038/ncb2926
  60. Samura, B. (2016). Galectin-3 as a predictor of statin treatment efficacy in patients with multiple myeloma. Georgian Medical News, 255, 56-61.
  61. Samura, B. B. (2016). Predictive value of circulating N-Terminal Pro-Brain Natriuretic Protein and VE-Catherin in patients with regression of multiple myeloma. Biological Markers and Guided Therapy, 3(1), 125-132. http://dx.doi.org/10.12988/bmgt.2016.6413

Downloads

How to Cite

1.
Samura BB, Panasenko MO. Cardiovascular events after polychemotherapy of multiple myeloma: modern ways to diagnostics. Current issues in pharmacy and medicine: science and practice [Internet]. 2020Mar.10 [cited 2026Jun.26];13(1). Available from: https://pharmed.zsmu.edu.ua/article/view/198217

Issue

Vol. 13 No. 1 (2020)

Section

Review

License

Authors who publish with this journal retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
 Лицензия Creative Commons